Although the anti-apoptotic eect of Bcl-2 is well established, the role of Bcl-2 in tumour response to therapy and drug resistance is still unclear. The posttranslational modi®cations of Bcl-2 are likely involved in the control of the apoptotic pathway. In the present study we have investigated the role of Bcl-2 in cellular response to oxidative stress (hydrogen peroxide) and cisplatin using a clone of human metastatic melanoma, which, in spite of Bcl-2 (over)expression, exhibited a moderate chemosensitivity. With both treatments melanoma cells died through an apoptotic process, associated with detachment of cells from the monolayer. In thē oating apoptotic cells generated by either hydrogen peroxide or cisplatin, along with morphological and biochemical features of apoptosis, we detected a signi®cant Bcl-2 cleavage, yielding the Bax-like fragment of 23 kDa. Preincubation of cells with the caspase-3/-7 inhibitor DEVD-CHO completely suppressed Bcl-2 cleavage, thus con®rming that such a speci®c proteolysis requires activation of caspase-3/-7. The oxidant-and cisplatin-induced processing of Bcl-2 documented in the present study may represent a regulatory mechanism to circumvent the survival function of Bcl-2 upon apoptosis triggering and to enhance apoptotic response. Since the Bcl-2 cleavage should be regarded as a pro-apoptotic event, Bcl-2 expression is expected to increase susceptibility to apoptosis. Thus, such a pathway could be exploited to improve the ecacy of cytotoxic therapy of melanomas expressing Bcl-2. Oncogene (2001) 20, 4591 ± 4595.
Apoptosis is an essential homeostatic mechanism that balances cell proliferation with cell death and maintains the correct cell number in a tissue, either in physiological or in pathological conditions (Jacobson et al., 1997; Thompson, 1995) . Defects in regulation of apoptosis are expected to contribute to tumour progression and metastatic dissemination. Resistance to apoptosis would provide cancer cells with a selective growth advantage and with ability to survive after cell detachment from extracellular matrix (Lowe and Lin, 2000; Ruoslahti and Reed, 1994) .
The aspartate-speci®c proteases known as caspases are widely recognized to play a key role in the initiation, eector, and degradation phases of apoptotic cell death, by cleaving a number of proteins essential for cell integrity (Nicholson and Thornberry, 1997; Martin and Green, 1995) . The caspase death eector machinery is negatively controlled by members of Bcl-2 family (Yang and Korsmeyer, 1996) . Several independent functions of Bcl-2 have been demonstrated, including the abrogation of mitochondrial release of caspase-activating factors (such as cytochrome c) (Kluck et al., 1997) , the modulation of antioxidant pathways (e.g. through the sequestration of glutathione to the nucleus) (Voerhinger et al., 1998) , and the regulation of calcium homeostasis (Marin et al., 1996) . Although the precise mechanism of Bcl-2 action remains to be fully elucidated, its (over)expression has been shown to prolong cell survival by delaying or blocking apoptosis induced by numerous physiological and pathological stimuli (Reed, 1997) .
In a few experimental models an alternative role for Bcl-2 has been recently identi®ed, showing that this protein can also serve as a physiological caspase substrate in apoptotic cells (Fujita and Tsuruo, 1998; Fadeel et al., 1999; Grandgirard et al., 1998; Cheng et al., 1997) . Such a caspase-mediated cleavage brings about the release of the BH4 domain from Bcl-2, with formation of a Bax-like fragment. Thus, in the present investigation we used the human metastatic melanoma cells Me665/2/21, expressing signi®cant amounts of Bcl-2, to evaluate the cellular response to hydrogen peroxide (H 2 O 2 ) or cisplatin, and the fate of Bcl-2 upon apoptosis induction.
Following exposure to H 2 O 2 or cisplatin, cell proliferation, as evaluated by the total cell number (monolayer plus supernatant), was signi®cantly aected with both cytotoxic treatments (Figure 1 ). Concurrently with the decrease of cell number in the monolayers, an increasing number of¯oating cells were shed in the culture medium, as a ®rst indication for ongoing cell death, in which cellular detachment and cytoskeleton disruption occur. As revealed upon DNA staining with Hoechst dye and observation under uorescence microscope, the majority of the detached cells from both treatments (Figure 2b and c) showed morphological changes typical of apoptosis, including condensed and highly¯uorescent chromatin, fragmented and/or smaller nuclei compared to control sample ( Figure 2a ). The percentage of such apoptotic nuclei was 84+4 and 92+4 (mean+s.e. n=3), for H 2 O 2 -and cisplatin-treated cells, respectively. The characteristic nuclear morphology was accompanied by cellular shrinkage, as routinely revealed by the optical observation performed during sample manipulations (not shown). The majority of attached cells of H 2 O 2 -treated sample retained a nuclear morphology comparable to untreated nuclei, while several apoptotic nuclei were found in still adherent cell population of cisplatintreated sample (not shown). To better characterize the mode of cell death induced by H 2 O 2 , we evaluated a biochemical parameter which is among the hallmarks of apoptosis, i.e. the speci®c caspase-mediated processing of the PARP molecule from its native form of 116 kDa to an inactive fragment of 90 kDa. After 24 h of H 2 O 2 poisoning, the typical apoptotic fragment of 90 kDa was uniquely observed in detached cells, while in control cells, and in adherent cells from H 2 O 2 -treated sample no PARP cleavage was observed ( Figure 3) . As a con®rmatory test to assess the apoptotic mode of cell death induced by H 2 O 2 or cisplatin, caspase-3/-7 activity (caspase-3-like DEVDase activity) was directly measured in cell extracts of control and treated samples. In H 2 O 2 -poisoned sample, caspase-3/-7 activity of the adherent cells had a marginal increase compared to control cells, while the detached cells, which produced the apoptotic PARP fragment, exhibited a marked increase of caspase-3/-7 activity ( Figure 4a ). Similarly, in cisplatin-treated cells caspase-3/-7 activity was extremely high in the¯oating cells; it was lower, but still signi®cantly higher than control, in the adherent cells, which exhibited a lower but considerable amount of apoptotic nuclei. The expression and integrity of Bcl-2 was examined by Western blot. As shown in Figure 5 , untreated cells expressed signi®cant amounts of Bcl-2 protein. Interestingly, in the¯oating cells of both H 2 O 2 -and cisplatin-treated cells, exhibiting morphological and biochemical parameters of apoptosis, a Bcl-2 fragment of approximately 23 kDa was evident. Since the antibody used by us recognizes the variable loop domain (amino acids 41 ± 54) of Bcl-2 and the fragment size detected corresponds to that previously reported (Cheng et al., 1997) , the cleavage fragment we found in the apoptotic cells of both treatments is consistent with a Bcl-2 cleavage at Asp residue 34 and/or 31, as recently described in a few dierent experimental models. The appearance of such a proteolytic fragment was not accompanied by quantitative loss of the fullsize Bcl-2. The per cent values of Bcl-2 cleavage were 29 and 32%, for H 2 O 2 -and cisplatin-derived apoptotic cells, respectively, as evaluated by densitometric analysis. To obtain further proof for the notion that Bcl-2 cleavage was caspase-3/-7-dependent, we preincubated H 2 O 2 -and cisplatin-treated melanoma cells . The number of both adherent and¯oating cells from untreated and treated samples is expressed as fold increase over cell number at 0 time. Data are means+s.e. of 2 ± 6 separate experiments. Me665/2/21 human melanoma cells were cultured in RPMI 1640 medium (Gibco) containing 10% heat-inactivated foetal calf serum (FCS) (Gibco), as described in Maellaro et al., 2000 . Cells were routinely harvested by phosphate-buered saline (PBS)-EDTA (0.2 g/l) and reseeded before reaching con¯uence. For proliferation experiments, the adherent cells were detached by EDTA treatment, and both adherent and¯oating cells were counted using a BuÈ rker chamber. For all subsequent experiments and determinations the treatments with 90 mM H 2 O 2 for 24 h and with 3.3 mM cisplatin for 48 h were chosen. These cytotoxic concentrations and exposure times were adequate to generate a sucient number of detached apoptotic cells to perform various assays, in conditions of a minor incidence of secondary late events (e.g. loss of plasma membrane integrity) in the presence of the cell permeable caspase-3/-7 inhibitor ac-DEVD-CHO (50 mM), which aorded a complete abrogation of Bcl-2 cleavage in both treatments ( Figure 5 ). As expected, under these conditions caspase-3/-7 activity was eciently inhibited down to basal levels, comparable to control values (Figure 4) . In summary, in the present study we show that the metastatic melanoma cells Me665/2/21, in spite of Bcl-2 (over)expression, are susceptible to killing by both H 2 O 2 and cisplatin, two DNA-damaging agents known to induce dierent types of DNA lesions (Schraufstatter et al., 1986; Chu, 1994) . Cell death occurs through apoptosis, as indicated by several parameters regarded as classical features of apoptosis. The most interesting observation is the cleavage of Bcl-2, yielding the 23 kDa fragment we observed in the apoptotic cells deriving from both treatments. Such a caspasemediated Bcl-2 cleavage has been previously described in a few models of mammalian cells triggered by dierent apoptotic stimuli, including Fas-ligation, alphavirus infection or etoposide (Fujita and Tsuruo, 1998; Fadeel et al., 1999; Grandgirard et al., 1998) , as well as in in vitro studies using recombinant caspase-3 (Cheng et al., 1997) . Thus, for the ®rst time, our study documents the involvement of Bcl-2 cleavage during apoptosis induced in melanoma cells by oxidative stress and a DNA-damaging agent. With respect to the protease(s) responsible for Bcl-2 cleavage, diverse evidences have been provided (Fadeel et al., 1999; Grandgirard et al., 1998; Cheng et al., 1997; Yamamoto et al., 1998) . In our cellular model, the absence of Bcl-2 cleavage fragment in the viable and still adherent cells of both treatments is consistent with the caspase-3/-7 activity, which was extremely high only in detached apoptotic cells while negligible (H 2 O 2 -treated) or signi®cantly lower (cisplatin-treated) in adherent cells. Furthermore, the formation of such a Bcl-2 fragment induced by both drugs was suppressed in the presence of the caspase-3/-7 inhibitor ac-DEVD-CHO, thus con®rming a major involvement of caspase-3/-7 in the processing of Bcl-2.
The caspase-3-catalyzed Bcl-2 cleavage at Asp 34 removes the NH 2 -terminal 1 ± 34 amino acids containing BH4 domain, which is required to inhibit apoptosis (Hirotani et al., 1999) . Thus, similarly to the fate of other caspase substrates, whose integrity is crucial for the homeostatic prevention of apoptosis, Bcl-2 cleavage appears to inactivate its function in cell survival. An additional eect has been envisaged however, since the Bax-like fragment deriving from Bcl-2 cleavage could also exert a pro-apoptotic function, through the release of cytochrome c in the cytosol and ampli®cation of the After ®xation in 3.7% p-formaldehyde, cells were permeabilized with 0.1% Triton X-100 and chromatin was stained with thē uorescent dye Hoechst 33258 (1 mg/ml) (Sigma). The nuclear morphology was observed with a¯uorescence microscope (Nikon), equipped with 330/380 nm excitation ®lter, and LP 440 nm barrier ®lter. For each sample, images were collected from dierent areas of the specimen glass slide and a total of 200 ± 250 nuclei was scored Figure 3 Cleavage of PARP protein induced in Me665/2/21 melanoma cells by H 2 O 2 (90 mM for 24 h). Lane 1, control; lanes 2 and 3, adherent and¯oating cells, respectively, of H 2 O 2 -treated sample. U937 cells were used as comparative positive test: lane 4, etoposide (100 mM for 3 h); lane 5, control. The bands corresponding to intact (116 kDa) and cleaved (90 kDa) PARP are indicated. A typical experiment of three is reported; repeated experiments gave fully comparable results. The analysis of PARP protein was performed by Western blot as previously described (Del Bello et al., 1999) , using a mouse monoclonal antibody (clone C-2-10, supplied by Dr GG Poirer, Quebec, Canada) caspase cascade (Cheng et al., 1997; Kirsch et al., 1999) . It is conceivable that Bcl-2 fragment can modulate cell death by multiple mechanisms. Among these, NH 2 -terminal BH4 domain of Bcl-2 has been shown to be functional for heterodimerization with Bax and inhibition of apoptosis (Reed, 1994) . Thus, it can be envisaged that a BH4-lacking Bcl-2 would favour the formation of the pro-apoptotic homodimers of Bax. This could be the case of the melanoma 2/21 cell clone we have used in this study, in which Bax protein is signi®cantly expressed (Perego et al., unpublished data). The view that Bcl-2 cleavage could paradoxically represent a mechanism to propagate the apoptotic cascade is in some way supported by preliminary results we obtained with a dierent cell clone ± deriving from the same metastatic melanoma Me665 ± in which Bax expression is comparable to that of 2/21 clone, while Bcl-2 protein is undetectable. This Bcl-2 lacking clone is paradoxically much less prone than 2/21 clone to undergo both H 2 O 2 -induced and cisplatin-induced apoptosis (Del Bello et al., unpublished data) .
In this perspective, Bcl-2 expression in cancer cells should be reconsidered from a dierent point of view, which could reconcile con¯icting results on the role of Bcl-2. According to the major paradigm, the (over)-expression of Bcl-2 is regarded as a negative prognostic parameter for clinical outcome, sparing tumour cells from spontaneous apoptosis and contributing to chemotherapy resistance (Reed, 1994) . But actually, in several human carcinoma cells, high Bcl-2 levels (either naturally occurring or increased through gene transfection) have been shown to confer a trend toward sensitivity rather than resistance to platinum drugs (Beale et al., 2000) . Furthermore, an inhibition of solid tumour cell growth by Bcl-2 has also been reported (Pietempol et al., 1994) . As far as melanoma cells are concerned, the role of Bcl-2 as a prognostic marker is particularly controversial. Immunohistochemistry and Western blot studies in human specimens have shown that normal epidermal melanocytes and melanocytic nevi constitutively express Bcl-2 protein, while the majority of primary cutaneous melanomas and even more cutaneous or lymph node metastases are negative for Bcl-2 or display only weak and focal expression (Van den Oord et al., 1994; Cerroni et al., 1995; Tron et al., 1995; Tang et al., 1998) . Such a down-regulated expression of the anti-apoptotic Bcl-2 oncoprotein in melanomas and their metastases seems to be con¯icting with the malignant behaviour of these neoplasms. On the other hand, the metastatic melanoma cell clone used in this study presented with a signi®cant Figure 4 Caspase-3/7 activity in Me665/2/21 melanoma cells. Cells were exposed to 90 mM H 2 O 2 for 24 h (panel A) or 3.3 mM cisplatin for 48 h (panel B), in the absence or presence of caspase-3 inhibitor ac-DEVD-CHO (50 mM) (ac-Asp-Glu-Val-Asp-aldehyde, Alexis Corp.), added to culture medium 1 h before drug treatments. Data are means+s.e. of 3 ± 5 separate experiments. The caspase-3/-7-like activity was measured as cleavage of thē uorogenic substrate ac-DEVD-AMC (ac-Asp-Glu-Val-Asp-7-amido-4-methylcoumarin) (Alexis), essentially according to Brockhaus and BruÈ ne, 1998 . The cleavage activity was evaluated as AMC release, monitored in a¯uorescence spectrophotometer (excitation/emission wavelengths: 380/460 nm). The speci®city of the cellular extracts for the substrate ac-DEVD-AMC cleavage was con®rmed in selected samples by adding the competitive aldehyde inhibitor ac-DEVD-CHO in vitro to cell lysates; in these conditions the¯uorogenic substrate cleavage was completely inhibited (data not shown) Figure 5 Expression and cleavage of Bcl-2 in Me665/2/21 melanoma cells. Cells were exposed to 90 mM H 2 O 2 for 24 h or 3.3 mM cisplatin for 48 h, in the absence or presence of caspase-3/-7 inhibitor ac-DEVD-CHO (50 mM) added to culture medium 1 h before drug treatments. The bands corresponding to intact (26 kDa) and cleaved (23 kDa) Bcl-2 are indicated. Lanes 1, 2, 4, 6, and 8: adherent cells; lanes 3, 5, 7, and 9:¯oating cells. Lane 1: control cells at 0 time. The experiment reported is representative of three separate experiments, giving fully comparable results. Bcl-2 expression and integrity was evaluated by Western blotting (Grandgirard et al., 1998) , using a monoclonal anti-human bcl-2 mouse antibody (clone bcl-2-100, Sigma). Protein bands were visualized by enhanced chemiluminescence (Roche) and subsequently subjected to densitometric analysis (densitometer apparatus and Molecular Analyst software, BioRad) sensitivity to oxidant-and cisplatin-induced apoptosis, in spite of high levels of Bcl-2 expression. This apparent discrepancy can conceivably result from the biological interplay of Bcl-2 with the complex network of anti-and pro-apoptotic oncoproteins. Alternatively, a possible explanation comes from the observation that Bcl-2 cannot inhibit apoptosis in several situations, suggesting that speci®c caspases may bypass the pathway inhibited by Bcl-2, or the anti-apoptotic capacity of Bcl-2 may be in some way overwhelmed. In such speci®c cellular contexts, Bcl-2 cleavage, rather than circumventing the death-antagonist function of Bcl-2 (or besides doing it), converts this protein to a death-agonist, which ampli®es the apoptotic cascade through a positive feedback loop of caspase activation.
New insights in the molecular regulation of apoptosis are particularly interesting for human melanoma, a common neoplastic disease, with an incidence growing faster than any other solid malignancy (Rigel et al., 1996) . Advanced-stage and metastatic melanomas, as well as melanoma-derived cell lines, have low spontaneous rate of apoptosis and are commonly refractory to conventional treatments, such as chemotherapy and radiation therapy (Serrone and Hersey, 1999) . Since many antineoplastic drugs kill susceptible cells by committing them to apoptosis, the study of such a process would contribute to clarify the mechanisms of melanoma chemoresistance. In particular, in Bcl-2 overexpressing melanomas, the pathway involving Bcl-2 cleavage might be exploited to improve the ecacy of cytotoxic therapies.
